logo
logo

Gandeeva Raises $40M In Series A Funding To Develop Novel Therapies Based On Precision Imaging Of Protein-Drug Interactions

Jan 31, 2022•over 3 years ago

Amount Raised

$40 Million

Round Type

series a

Vancouver

Description

Gandeeva Therapeutics, a precision biotechnology company harnessing the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop novel therapeutics at an accelerated pace, today announced it has raised US$40 million in Series A funding led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures, Amplitude Ventures and Air Street Capital.

Company Information

Company

Gandeeva Therapeutics

Location

Vancouver, Washington, United States

About

Gandeeva™ is a precision biotechnology company harnessing the power of cryo-electron microscopy (cryo-EM) and machine learning to advance drug discovery and development at scale. Gandeeva Founder and CEO, Sriram Subramaniam is recognized internationally for his leadership in driving the cryo-EM resolution revolution and for innovations in 3D electron microscopic imaging. Gandeeva seeks to achieve transformative societal impact on public health by revolutionizing drug discovery and by lowering risks of late-stage clinical failures. Gandeeva is based in Vancouver, Canada. For more information, visit www.gandeeva.com or follow @Gandeeva_Tx on Twitter.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech